# Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing

> **NCT05344248** · PHASE1,PHASE2 · COMPLETED · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 183 (actual)

## Conditions studied

- Moderate to Severe Psoriasis

## Interventions

- **BIOLOGICAL:** JS005 (recombinant humanized monoclonal antibody against IL-17A)
- **BIOLOGICAL:** JS005 placebo

## Key facts

- **NCT ID:** NCT05344248
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-20
- **Primary completion:** 2022-10-28
- **Final completion:** 2022-11-01
- **Target enrollment:** 183 (ACTUAL)
- **Last updated:** 2022-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05344248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05344248, "Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05344248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*